Peru's medicines regulator, part of the Ministry of Health. A 2025 law requires it to decide within 45 calendar days on cancer and rare-disease medicines already registered and sold in a high-surveillance country, or the application is approved by default.
DIGEMID is the Ministry of Health's general directorate for medicines and the national authority for pharmaceutical products under Ley 29459. In December 2024 it stated that it then had 2,200 medicine registration files in process, 86% of them filed that year, and that its average wait for registration was 2.8 months for biological products and 4.9 months for synthetic medicines; that Ley 31738 of May 2023 already gave a 45-calendar-day accelerated procedure for rare, orphan and cancer medicines from high-surveillance countries (países de alta vigilancia sanitaria), under which it had granted four registrations; and that 14 of 55 foreign factories it inspected that year failed its manufacturing standards. Ley 32319, signed on 30 April 2025, exempts medicines and biological products for rare and orphan diseases, cancer and other diseases that are registered and sold in a high-surveillance country from articles 10 and 11 of Ley 29459, and subjects them to an accelerated evaluation of no more than 45 calendar days with positive administrative silence, provided the full quality, safety and efficacy dossier in common technical document format, climate zone IV-A or IV-B stability studies, a certificate of pharmaceutical product, a risk management plan and Spanish labelling are filed; it repealed article 9 of Ley 29698, the rare diseases law, which Ley 31738 had added. In the same December 2024 statement DIGEMID had opposed a bill for automatic registration, arguing that no regulator grants it. Ley 31336 of 2021 declares the technological strengthening of DIGEMID and the national health institute for health technology assessment of cancer resources to be of national interest.
Shares Seguro Integral de Salud (SIS), Peru, Ministerio de Salud del Perú (MINSA), Global oncology and access in low- and middle-income countries.
Shares Seguro Integral de Salud (SIS), Peru, Ministerio de Salud del Perú (MINSA).
Shares Seguro Integral de Salud (SIS), Peru, Ministerio de Salud del Perú (MINSA), Global oncology and access in low- and middle-income countries.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/